Interferon beta 1b (IFN-β1b)

Study Reference
Colvin (IFN beta-1b only), 2010

Colvin Linking a pharmaceutical claims database with a birth defects registry to investigate birth defect rates of suspected teratogens. Pharmacoepidemiol Drug Saf 2010; 19:1137-50

Fragoso (control exposed to Glatiramer), 2013

Fragoso Long-term effects of exposure to disease-modifying drugs in the offspring of mothers with multiple sclerosis: a retrospective chart review. CNS Drugs 2013; 27:955-61

Fragoso (control unexposed, sick), 2013

Fragoso Long-term effects of exposure to disease-modifying drugs in the offspring of mothers with multiple sclerosis: a retrospective chart review. CNS Drugs 2013; 27:955-61

Nguyen (control exposed to Glatiramer), 2019

Nguyen Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. Mult Scler Relat Disord 2019; 28:235-243

Nguyen (control unexposed, sick), 2019

Nguyen Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. Mult Scler Relat Disord 2019; 28:235-243

Weber-Schoendorfer (control exposed to Glatiramer), 2009

Weber-Schoendorfer Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult. Scler. 2009; 15:1037-42

Weber-Schoendorfer (control unexposed, disease free), 2009

Weber-Schoendorfer Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult. Scler. 2009; 15:1037-42

Weber-Schoendorfer (control unexposed, sick), 2009

Weber-Schoendorfer Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult. Scler. 2009; 15:1037-42